TrialSignal
Clinical trial intelligence report
Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02299817
Status
UNKNOWN
Phase
PHASE2
Sponsor
Olof Skoldenberg
Executive brief
Investment-Ready Snapshot
This clinical trial investigates the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants in total hip arthroplasty. The study aims to provide insights into the potential of denosumab as a treatment option for patients experiencing osteolysis post-surgery.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02299817
Indication
Osteolysis
Modality
monoclonal antibody
Target
Osteolysis
Intervention
Denosumab, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.